DOI:
10.18413/2313-8955-2015-1-3-164-171
Role of metabolic endotoxemia in the development of cardiovascular and metabolic diseases
Intestinal microbiom is the one of potential source for development metabolic endotox-emia (a two- to threefold increase in serum concentrations of endotoxins). In this review, we discuss the potential causes, molecular implications and role of metabolic endotoxemia in the development of cardiovascular and metabolic diseases for their diagnosis, prevention,and treatment.
Number of views: 2289 (view statistics)
Количество скачиваний: 5278
Information for citation:
Kostina DA, Pokrovskaia TG, Martynova OV, et al. Role of metabolic endotoxemia in the development of car-diovascular and metabolic diseases. Research Result. Medicine and Pharmacy Series. 2015;1(3):164-171 (In Russian). DOI: 10.18413 / 2313-8955-2015-1-1-164-171
While nobody left any comments to this publication.
You can be first.
1. Arutyunov GP, Bylova NA Rumyantsev SA Ex-tracardiac manifestations in chronic heart fail-ure. – Мoscow, 2013 – 172с.
2. Vertkin AL , Skotnikov A. , M. Gubzhokova Co-morbidity in chronic obstructive pulmonary disease : the role of chronic systemic inflam-mation and clinical pharmacology of roflumi-last // Therapist. 2013. № 9. P. 85–88.
3. The effect of antioxidants on endothelial dysfunction in modeling L-NAME- induced deficiency of nitric oxide / Yakushev V.I [et al.] // Kuban Scientific Herald. 2010 №9 (123). P. 186-190
4. Egorova E.N., Kalinkin M.N., Mazur E.S. Sys-temic inflammation in the pathogene-sis of chronic heart failure // Verhnevolzhskiy Med-ical Journal. 2012. V.10 (1). P. 16-18.
5. Kazyulin AN, Shestakov VA, Babin SM The role of endotoxemia in the pathogenesis of NASH // Gastroenterology. 2014. №1. P. 18-21
6. Cellular and humoral immune mechanisms antiendotoxin patients with rheumatoid ar-thritis / Beloglazova K.V. [et al.]// Tauride biomedical Gazette. 2009. V.12, N3. P. 10-14
7. Petukhov VA Dysbiosis, endotoxin aggression, abnormal liver function and endothelial dys-function in surgery. Modern approach to the problem // Therapist. 2006. V.4, №4. P. 10-15
8. Principles of pharmacological correction of endothelial dysfunction / Pokrovskaya T. G. [et al.] // Kuban Scientific Herald. 2007. № 1-2. P. 146-149.
9. Realities and prospects for pharmacological correction of «ADMA-eNOS»-associated ways in preeclampsia Pokrovsky M.V. [et al.] // Ra-tional Pharmacotherapy in Cardiology. 2010. № 6. P. 882-887.
10. Method of endothelial dysfunction modeling by simulating the metabolic disorders / May-akov A.I. [et al.] // Belgorod State University Scientific bulletin Medicine Pharmacy. 2011. №10(105), issue 14. P. 196-201.
11. A human model of inflammatory car-dio-metabolic dysfunction; a double blind placebo-controlled crossover trial / Meh-ta N.N. [et al.] // J Transl Med. 2012; 10. P. 124.
12. Association between Toll-like receptors and the extent and severity of coronary ar-tery disease in patients with stable angina. / Mizoguchi E. [et al.] // Coron Artery Dis. 2007. 18(1). P. 31-8.
13. Association of endotoxemia with carotid ath-erosclerosis and cardiovascular disease: pro-spective results from the Bruneck Study. / Wiedermann C.J. [et al.]. // J Am Coll Cardiol. 1999. 34(7). P.1975-81.
14. Atorvastatin suppresses LPS-induced rap-id upregulation of Toll-like receptor 4 and its signaling pathway in endothelial cells. / Wang Y. [et al.] // Am J Physiol Heart Circ Physiol. 2011. 300(5). P. 1743-52.
15. Bacterial endotoxin and non-alcoholic fat-ty liver disease in the general population: a prospective cohort study / Wong V.W. [et al.] // Aliment Pharmacol Ther. 2015. 42(6). P.731-40. Brade H. Endotoxin in Health and Disease. NY: CRC Press, 1999. 968.
16. Causes and consequences of low grade endo-toxemia and inflammatory diseases / Glaros T.G. [et al.]// Frontiers in Bioscience. 2013. V.5. P. 754-65.
17. Characterization of inflammation and immune cell modulation induced by low-dose LPS administration to healthy volun-teers / Dillingh M.R. [et al.] // J. of Infl. 2014. 11:28 URL: http://www.journal-in-flammation.com/content/11/1/28 (дата обращения 07.12.2015).
18. Chronic endotoxemia and endothelium-depen-dent vasodilation in coronary arteries. / Myers P.R. [et al.]// Shock. 1996. 6(4). P.267-73.
19. Circulating endotoxemia: a novel factor in
systemic inflammation and cardiovascular disease in chronic kidney disease. / McIn-tyre C.W., [et al.]// Clin J Am Soc Nephrol. 2011. 6(1) P.133-41.
20. Endotoxins and inflammation in hemodial-ysis patients. / El-Koraie A.F., [et al.] // He-modial Int. 2013. 17(3). P.359-65.
21. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. / Methe H. [et al.] // Circulation. 2005. 111(20). P. 2654-61.
22. Gnauck A., Lentle R.G., Kruger M.C. The characteristics and function of bacterial li-popolysaccharides and their endotoxic po-tential in humans // Int Rev Immunol. 2015.25. P. 1-31.
23. Human endotoxemia as a model of system-ic inflammation / Andreasen A.S. [et al.] // Curr Med Chem. 2008. 15(17). P. 1697-705.
24. Human experimental endotoxemia in model-ing the pathophysiology, genomics, and ther-apeutics of innate immunity in complex car-diometabolic diseases. / Patel P.N. [et al.] // Arterioscler Thromb Biol. 2015. 35(3). P. 525-
25. Immunopathogenesis of atherosclero-sis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. / Lehr H.A [et al.] // Circulation. 2001. 104. P. 914–920.
26. Lipopolysaccharide-binding protein (LBP) is associated with total and cardiovascular mortality in individuals with or without sta-ble coronary artery disease / Lepper P.M., [et al.] // Atherosclerosis. 2011. 219(1). P. 291–710.
27. Marshall J.C. Lipopolysaccharide: an endo-toxin or an exogenous hormone? // Clin In-fect Dis. 2005. 41 Suppl 7. P. 470-80.
28. Metabolic endotoxemia: a molecular link between obesity and cardiovascular risk / Neves A.L. [et al.] // J Mol Endocrinol. 2013. 51(2). P. 51-64.
29. Milosh T.S., Maksimovich N.Y. The endo-thelium of the vessels and proxidative-an-tioxidative balans in pregnancy rats with endothoxinaemia // Patol Fiziol Eksp Ter. 2015. 59(1). P.55-9.
30. Probiotics as Complementary Treatment for Metabolic Disorders / Le Barz M. [et al.]// Diabetes Metab J. 2015. 39(4). P. 291-303.
31. Punder K., Pruimboom L. Stress Induces Endotoxemia and Low-Grade Inflammation by Increasing Barrier Permeability // Front Immunol. 2015; 6. P. 223.
32. Relationship between microbial transloca-tion and endothelial function in HIV infect-ed patients. / Blodget E. [et al.] // PLoS One. 2012. 7(8) P. 4262-4.
33. Role of angiotensin II in endothelial dys-function induced by lipopolysaccharide in mice. / Lund D.D. [et al.] // Am J Physiol Heart Circ Physiol. 2007. 293(6). P. 3726-31
34. Role of gut microbiota in the modulation of atherosclerosis-associated immune re-sponse / Chistiakov D.A. [et al.]// Front Mi-crobiol. 2015. 6 P.671.
35. Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn’s Disease / Guo Y. [et al.] // Mediators Inflamm. 2015 URL: http://www.ncbi.nlm.nih.gov/pmc/ar-ticles/PMC4464677/ (дата обращения 06.12.2015)
36. Significance of systemic endotoxaemia in in-flammatory bowel disease / Gardiner K.R. [et al.] // Gut. 1995. 36(6). P. 897–901.
37. The gut microbiome as novel cardio-meta-bolic target: the time has come! / Vinjé S. [et al.] // Eur Heart J. 2014. 35(14). P. 883-7.
38. Verma I. Nuclear factor (NF)-κB proteins: therapeutic targets // Ann Rheum Dis. 2004. 63(Suppl 2). P. 57–61.